MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// Akriti Kharbanda, Hasan Rajabi, Caining Jin, Maroof Alam, Kwok-Kin Wong, Donald Kufe Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215 Correspondence to: Dr. Donald Kufe, e-mail: donald_kufe@dfci.harvard.edu . Key words: KRAS, NSCLC, MUC1-C, AKT, ZEB1, EMT, self-renewal Abbreviations: NSCLC, non-small cell lung cancer; MUC1, mucin 1; MUC1-C, MUC1 C-terminal subunit; EMT, epithelial-mesenchymal transition; MET, mesenchymal-epithelial transition Received: July 19, 2014 Accepted: August 17, 2014 Published: August 22, 2014 ABSTRACT Non-small cell lung cancers (NSCLCs) that harbor an oncogenic KRAS mutation are often associated with resistance to targeted therapies. The MUC1-C transmembrane protein is aberrantly overexpressed in NSCLCs and confers a poor outcome; however, the functional role for MUC1-C in mutant KRAS NSCLC cells has remained unclear. The present studies demonstrate that silencing MUC1-C in A549/KRAS(G12S) and H460/KRAS(Q61H) NSCLC cells is associated with downregulation of AKT signaling and inhibition of growth. Overexpression of a MUC1-C(CQC→AQA) mutant, which inhibits MUC1-C homodimerization and function, suppressed both AKT and MEK activation. Moreover, treatment with GO-203, an inhibitor of MUC1-C homodimerization, blocked AKT and MEK signaling and decreased cell survival. The results further demonstrate that targeting MUC1-C suppresses expression of the ZEB1 transcriptional repressor by an AKT-mediated mechanism, and in turn induces miR-200c. In concert with these effects on the ZEB1/miR-200c regulatory loop, targeting MUC1-C was associated with reversal of the epithelial-mesenchymal transition (EMT) and inhibition of self-renewal capacity. Loss of MUC1-C function also attenuated KRAS independence and inhibited growth of KRAS mutant NSCLC cells as tumors in mice. These findings support a model in which targeting MUC1-C inhibits mutant KRAS signaling in NSCLC cells and thereby reverses the EMT phenotype and decreases self-renewal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 3×
“Approximately 25% of patients with non-small cell lung cancer (NSCLC) harbor an oncogenic KRAS mutation that is often associated with resistance to conventional and targeted therapies [1].”
BackgroundInfluentialAKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · cited 1×
“In contrast to targeting the MUC1-C CQC motif with the MUC1-C(AQA) mutant or GO-203, the absence of MEK downregulation in response to stable MUC1-C silencing may represent a compensatory response to suppression of AKT, as has been observed in other settings [33].”
ResultPuyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · cited 1×
“GATA2 and CDK4 have also been shown to be of importance for the growth and survival of NSCLC cells expressing mutant KRAS [4, 5].”
BackgroundMolina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157 · cited 2×
“In a small molecule screen, mutant KRAS NSCLC cells were more sensitive to inhibition of the RAF→MEK→ERK pathway as compared to KRAS wild-type cells [6].”
BackgroundResult
Cited by
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Friedlaender, A., Drilon, A., Weiss, G. J., Banna, G. L., & Addeo, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101978 · Cited by 118
“The presence of EMT thus suggests the loss of KRAS oncogene addiction[20],[21].”
BackgroundLiang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R. R., Vassella, E., Yang, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0479-6 · Cited by 55
Detappe, A., Mathieu, C., Jin, C., Agius, M. P., Diringer, M.-C., Tran, V.-L., Pivot, X., Lux, F., Tillement, O., Kufe, D., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.06.069 · Cited by 27
Self-citation
Metadata
- Authors
- Kharbanda, A., Rajabi, H., Jin, C., Alam, M., Wong, K.-K., & Kufe, D.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-08-22
- Volume
- 5
- Issue
- 19
- Pages
- 8893-8905
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1853810791
- Cited by
- 65
- References
- 6
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. https://app.cochat.ai/papers/10.18632/oncotarget.2360
- The paper
- Kharbanda, A., Rajabi, H., Jin, C., Alam, M., Wong, K.-K., & Kufe, D. (2014). MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Oncotarget. https://doi.org/10.18632/oncotarget.2360
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.